---
id: topic-diabetes-translation-brief
type: topic
topic: diabetes
species: feline
disease: diabetes mellitus
question_type: translation
source_ids: [src-diabetes-006, src-diabetes-007, src-diabetes-008, src-diabetes-011, src-diabetes-015, src-diabetes-016, src-diabetes-017, src-diabetes-024]
last_compiled_at: 2026-04-24
confidence: low
verification_status: compiled
decision_grade: no
language_qa_status: light_checked
language_qa_notes: "2026-04-24 checked for paper-card verification-state sync; translation page remains branch-architecture guidance, not treatment recommendation."
owner: codex
status: active
---

# Feline Diabetes Translation Brief

## Key-Claim Traceability

| ID | Claim | Level | Source ids | Boundary |
|---|---|---|---|---|
| DT1 | Diabetes translation should be modeled as treatment branches rather than one ranked protocol | B | src-diabetes-006, src-diabetes-007, src-diabetes-008, src-diabetes-011, src-diabetes-015, src-diabetes-016, src-diabetes-017, src-diabetes-024 | compiled branch map; not treatment recommendation |
| DT2 | Diet and remission signals are important but need evidence labels before clinical ranking | B | src-diabetes-006, src-diabetes-007, src-diabetes-015, src-diabetes-016 | not diet prescription |
| DT3 | SGLT2 translation must stay behind safety/regulatory gates | B | src-diabetes-011, src-reg-010, src-reg-011, src-reg-012, src-reg-013 | no product superiority claim |
| DT4 | Treatment pages should not rank interventions before full-text review | C | src-diabetes-006, src-diabetes-024 | not decision-grade guidance |

## Working Frame

The translation branch should treat feline diabetes management as a layered system: diet and weight strategy, insulin choice, remission tracking, comorbidity control, and selected adjunct drug classes.

## Treatment Branches

- diet prevention and management: `src-diabetes-006`
- diet comparison studies: `src-diabetes-015`, `src-diabetes-016`, `src-diabetes-022`
- remission evidence boundary: `src-diabetes-007`
- alpha-glucosidase inhibitor plus low-carbohydrate diet: `src-diabetes-008`
- new treatment approaches: `src-diabetes-017`
- SGLT2 inhibitor frontier: `src-diabetes-011`
- insulin glargine U300: `src-diabetes-024`

## Tier A Translation Boundaries

- `src-diabetes-014` supports a clinical decision map around diet, insulin type and dose, monitoring strategy, concomitant therapy, complications, and client constraints.
- [diabetes remission boundary memo](../../system/indexes/diabetes-remission-boundary-memo.md) supports remission as a real goal but blocks simple protocol ranking because evidence quality is moderate to poor and no single factor predicts remission.
- `src-diabetes-005` supports obesity and diet management, but warns that stabilization may need to precede caloric restriction when cats present after weight and muscle loss.
- [diabetes diet architecture memo](../../system/indexes/diabetes-diet-architecture-memo.md) supports diet as prevention and management, but requires evidence labels because some diet guidance depends on clinical experience and physiologic reasoning where direct research is lacking.
- [diabetes endocrine-secondary diabetes memo](../../system/indexes/diabetes-endocrine-secondary-diabetes-memo.md) supports a secondary-endocrine branch that can change diagnosis and therapy logic.
- `src-diabetes-015` supports low-carbohydrate/low-fiber diet as a serious treatment branch in one randomized 16-week study, but not a universal diet rule.
- `src-diabetes-024` supports glargine U300 as a promising short-term insulin branch, but not superiority over other insulin protocols.
- [diabetes SGLT2 safety/regulatory boundary memo](../../system/indexes/diabetes-sglt2-safety-regulatory-boundary-memo.md) supports SGLT2 inhibitors as a real treatment branch for uncomplicated feline diabetes, governed by candidate selection, monitoring, residual beta-cell function, and euglycemic DKA risk.
- [diabetes SGLT2 primary FDA source memo](../../system/indexes/diabetes-sglt2-primary-fda-source-memo.md) upgrades the SGLT2 branch from review-abstract regulatory signal to U.S. primary-source-backed branch for Bexacat and Senvelgo, while preserving product-ranking and current-label caveats.
- [diabetes SGLT2 current label control memo](../../system/indexes/diabetes-sglt2-current-label-control-memo.md) adds current-label control for Bexacat and Senvelgo and reinforces insulin-naive and DKA/euglycemic-DKA boundaries.
- [diabetes SGLT2 label-section comparison memo](../../system/indexes/diabetes-sglt2-label-section-comparison-memo.md) prevents product-specific monitoring gates from being merged into a generic SGLT2 schedule.
- [diabetes treatment branch comparison memo](../../system/indexes/diabetes-treatment-branch-comparison-memo.md) separates diet, insulin, SGLT2, alpha-glucosidase adjunct, incretin/frontier, and remission-control branches.
- [diabetes diagnostic monitoring workup memo](../../system/indexes/diabetes-diagnostic-monitoring-workup-memo.md) keeps treatment translation tied to workup gates rather than one flat treatment ladder.
- [diabetes obesity body-condition memo](../../system/indexes/diabetes-obesity-body-condition-memo.md) makes stabilization, glycemic control, diet composition, and weight loss a staged sequencing issue rather than a simple calorie-restriction instruction.
- [diabetes pancreatitis comorbidity memo](../../system/indexes/diabetes-pancreatitis-comorbidity-memo.md) supports pancreatitis as a bidirectional comorbidity that can make diabetes and DKA management harder.
- `src-diabetes-008` supports an alpha-glucosidase inhibitor plus low-carbohydrate diet branch, but its combined intervention design blocks clean independent drug-effect claims.
- `src-diabetes-016` supports keeping low-carbohydrate and high-fiber diet claims as evidence-weighted options rather than slogans.
- `src-diabetes-017` maps incretin/GLP-1-related innovation before the SGLT2 era, but should not be treated as a mature feline protocol owner.
- `src-diabetes-022` adds a small high-protein/low-carbohydrate diet study with insulin-dose reduction signals, but it does not isolate protein from carbohydrate reduction.

## Guardrail

Treatment pages should not rank interventions from the current compiled layer alone. The paper-card base is now stronger, but the next needed gain is tighter topic/output-level compression and, where relevant, label-level precision. For now, the safe structure is branch separation, endpoint mapping, and safety-boundary control, not clinical recommendation.
